Abstracts tagged "B-Lymphocyte"

Abstract Number: 0607 • ACR Convergence 2023
CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained
Georg Schett¹, Luis Munoz², Jule Taubmann³, Michael Aigner⁴, Christina Bergmann⁵, Johannes Knitza⁶, Gerhard Kroenke⁷, Dagmar Werner², Fabian Müller⁸ and Andreas Mackensen⁴, ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²FAU Erlangen-Nürnberg, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁷Charite Berlin, Berlin, Germany, ⁸Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: We have previously shown that CD19 CAR T cell therapy leads to stable drug-free remission of treatment-resistant SLE (1,2). Based on these findings we…
Abstract Number: 2189 • ACR Convergence 2023
Lymphopenia Fluctuation Patterns Determine the Trajectory of the Disease in Sjogren’s Patients with Hematological Involvement
Giovanni Fulvio¹, Matilde Bandeira², Augusto Silva³, Gaetano La Rocca⁴, Silvia Fonzetti⁵, Francesco Ferro⁶, Marta Mosca⁷, Vasco Romão², Chiara Baldini¹, Manuel Silvério-António⁸ and Nikita Khmelinskii², ¹University of Pisa, Pisa, Italy, ²Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ³Santa Maria Hospital, Maceira, Portugal, ⁴University of Pisa, Rheumatology Unit, Pisa, Italy, ⁵AOUP, Pisa, Italy, ⁶Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁷Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁸Hospital Santa Maria, Lisboa, Portugal
Background/Purpose: Sjogren's disease (SjD) is characterized by a moderate prevalence of cytopenia, mainly neutropenia and lymphocytopenia with a typical fluctuating pattern. The associations between clinical…
Abstract Number: 0728 • ACR Convergence 2023
Systemic Lupus Erythematosus B Lymphocyte Responsiveness to Type I and Type III Interferon Is Determined by Donor IFN Status and B Cell Phenotype
Diana Alzamareh, Mary O'Connell, Jennifer Anolik and Jennifer Barnas, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematous (SLE) is a heterogenous autoimmune disorder characterized by pathogenic antinuclear antibodies. An interferon (IFN) gene signature and B cell aberrations are…
Abstract Number: 2341 • ACR Convergence 2023
Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
María laiño¹, Monica Enguita², Javier Loricera³, Clara Moriano Morales⁴, Carmen Lasa⁵, Vanesa Calvo Río⁶, Javier Narvaez⁷, Pablo Ignacio Navarro Guerra⁸, Ivette Casafont-Sole⁹, Judit Font Urgelles¹⁰, Adela Gallego¹¹, Irene Carrión-Barberà¹², Patricia Quiroga¹³, Santos Castañeda¹³, Angel Garcia-Aparicio¹⁴, Joaquin Maria Belzunegui Otano¹⁵, Juan Ramon De Dios¹⁶, Marta López¹⁷, Samuel Hernandez¹⁸, Sergi Heredia Martin¹⁹, Aaron Fariñas²⁰, Francisco Navarro²¹, Jorge Juan Fragio²², Carmen Escudero²³, Rafaela Ortega Castro²⁴, Leticia del Olmo Perez²⁵, Valvanera Pinillos²⁶, Eztizen Labrador²⁶, Mamen Ortega²⁷, Patricia Castro Pérez²⁷, Juan Maria Blanco-Madrigal²⁸, Marcos Paulino²⁹, María Ángeles Matías³⁰, Enrique Calvo-Aranda³¹, Cilia Peralta³², Silvia García³³, Jordi Camins-Fàbregas³⁴, Marta Garijo Bufort³⁵, Dolores Fabregas³⁶, Ana Urruticoechea³⁷, Miguel Medina Malone³⁸, Piter Jose Cossio Jimenez³⁹, Eva Perez-Pampin⁴⁰, Blanca Varas de Dios⁴¹, Carlos Vazquez Galeano⁴², Nuria Vegas Revenga⁴³, Olga Rusinovich⁴⁴, Emilio Giner-Serret⁴⁵, Jose Ramón lamúa⁴⁶ and Vicente Aldasoro¹, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Navarrabiomed-Unidad de Metodología, Pamplona, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital Universitario de León, León, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ⁶Valdecilla Hospital, Santander, Spain, ⁷Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Hospital Universitario German Trias i Pujol,, Badalona, Spain, ¹¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹²Hospital del Mar, Barcelona, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Hospital Universitario de Toledo, Toledo, Spain, ¹⁵University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁶Hospital Universitario Araba, Vitoria, Spain, ¹⁷Hospital Universitario Arava, Pamplona, Spain, ¹⁸Hospital Universitario Son Llatzer, Palma de Mallorca, Spain, ¹⁹Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁰Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²¹Doctor. Rheumatology, Alicante, Spain, ²²Hospital General Universitario Valencia, Valencia, Spain, ²³Hospital Universitario de Valme, Sevilla, Spain, ²⁴Hospital Reina Sofía, Cordoba, Spain, ²⁵Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain, ²⁶Hospital Universitario San Pedro, Logroño, Spain, ²⁷Hospital Universitario de Getafe, Getafe, Spain, ²⁸Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ²⁹Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ³⁰Hospital Universitario Infanta Leonor/Rheumatology Department, Madrid, Spain, ³¹Hospital Universitario Infanta Leonor, Madrid, Spain, ³²Hospital Clínico Lozano Blesa, Zaragoza, Spain, ³³Hospital Parc Taulí, Sabadell, Spain, ³⁴Hospital General de Granollers, Granollers, Spain, ³⁵Hospital de Sagunto, Valencia, Spain, ³⁶Hospital de Barbastro, Barbastro, Spain, ³⁷Hospital Can Misses, Ibiza, Spain, ³⁸Hospital Calahorra, Calahorra, Spain, ³⁹HOSPITAL REINA SOFIA, Tudela, Spain, ⁴⁰Rheumatology Department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ⁴¹Santa Cristina Universitary Hospital, Madrid, Spain, ⁴²ZARAGOZA, Madrid, Spain, ⁴³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴⁴Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ⁴⁵Hospital Royo Villanova, Teruel, Spain, ⁴⁶Hospital Universitario del Henares, Alcalá de Henares, Spain
Background/Purpose: Belimumab (BLM) is a monoclonal antibody that inhibits B-lymphocyte stimulating factor (BlyS), approved in 2011 as a treatment for systemic lupus erythematosus (SLE). We…
Abstract Number: 0729 • ACR Convergence 2023
ROCK1 Orchestrates B-cell Differentiation Under Stress
Juan Rivera-Correa¹, Sanjay Gupta¹, Edd Ricker², Danny Flores-Castro¹, Daniel Jenkins¹, Stephen Vulcano¹, Tania Pannellini¹, Matthew Miele³, Zhuoning Li³, Nahuel Zamponi⁴, Young-Bum Kim⁵, Evgenia Giannopoulou¹, Leandro Cerchietti⁴ and Alessandra Pernis¹, ¹Hospital for Special Surgery, New York, NY, ²Columbia University, New York, NY, ³Memorial Sloan Kettering Cancer Center, New York, NY, ⁴Weill Cornell Medicine, New York, NY, ⁵Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: The mechanisms utilized by B cells to execute their differentiation programs when exposed to damaging and stressful environments, which often accompany severe infections and…
Abstract Number: 2464 • ACR Convergence 2023
B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature
Erin Wilfong¹, Leslie Crofford² and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: Autoantibodies directed against various tRNA synthetases defines the anti-tRNA synthetase syndrome (ARS). While it is unclear if the autoantibodies are directly pathogenic, the efficacy…
Abstract Number: 0730 • ACR Convergence 2023
NF-κB Signaling Is Critically Important for Functional Responses of ACPA-producing B Cell Clones from Patients with Rheumatoid Arthritis
Giulia Frazzei¹, Jan Piet van Hamburg², Ronald van Vollenhoven² and Sander Tas³, ¹Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play a role in rheumatoid arthritis (RA) pathogenesis, and their presence is associated with disease severity. Consequently, detailed analysis of…
Abstract Number: 2465 • ACR Convergence 2023
Clonally Expanded B Cells in Anti-Histidyl-tRNA Synthetase Syndrome Patients Exhibit an Autoreactive-Prone Memory Phenotype and Bind Jo-1 Autoantigen
Lindsay Bass¹, Dena Liu¹, Alberto Cisneros², Jennifer Young-Glazer², Leslie Crofford³, Erin Wilfong² and Rachel Bonami², ¹Vanderbilt University, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: Anti-histidyl-tRNA synthetase syndrome (Jo-1 ARS) is defined by the presence of autoantibodies against histidyl tRNA synthetase (Jo-1). Clinically, Jo-1 ARS can involve multiple tissues…
Abstract Number: 0001 • ACR Convergence 2023
Loss of the Complement Regulator CD55 Alters Marginal Zone B Cell Homeostasis
Iris Lee¹, Sonam Verma², Ivana Ling², Christine Pham³ and Peggy Kendall², ¹Washington University in St. Louis, St. Louis, MO, ²Washington University, Saint Louis, MO, ³Washington University, St. Louis, MO
Background/Purpose: Complement and B cells are implicated in the pathophysiology of rheumatoid arthritis, an autoimmune disease characterized by synovial inflammation. Loss of complement regulator CD55…
Abstract Number: 0732 • ACR Convergence 2023
Should Complete B-cell Depletion Be Maintained in Patients Treated Long-term with Rituximab for Rheumatoid Arthritis?
Roba Ghossan¹, Omar AL TABAA², Alice Combier³, Alexia STEELANDT³, Marion THOMAS³, Olivier Fogel³, Corinne MICELI⁴, Anna Molto³ and Jérôme Avouac⁵, ¹COCHIN HOSPITAL, Paris, France, ²APHP / Cochin Hospital, Paris, France, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Université de Paris Cité, HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France
Background/Purpose: Complete peripheral B cell depletion has been considered as a relevant indicator of short-term response to rituximab (RTX) in rheumatoid arthritis (RA). The purpose…
Abstract Number: 2466 • ACR Convergence 2023
Monoclonal Anti-MDA5 Autoantibodies Derived from a Patient with Dermatomyositis Target the Hel2i Domain of the MDA5 Protein
Eveline Van Gompel¹, Ragnhild Stålesen², Caroline Grönwall², Annika van Vollenhoven², Lena Israelsson², Ingrid Lundberg³, Vivianne Malmström², Karine Chemin⁴ and Vijay Joshua², ¹Karolinska Institutet - KU Leuven, Leuven, Belgium, ²Karolinska Institutet, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The strong clinical association between the anti-MDA5 autoantibodies and the development of severe lung disease in patients with dermatomyositis (DM) suggests an active role…
Abstract Number: 0003 • ACR Convergence 2023
Expanded Extrafollicular B Cells Were Improved by RTX in IgG4-related Disease
Yusho Ishii¹, Aakriti Alisha Arora¹, Scott Jenks¹, Iñaki Sanz² and Arezou Khosroshahi¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated disease characterized by fibrotic masses with expansion of IgG4-producing plasma cell in multiple organs such as pancreas, lacrimal…
Abstract Number: 0924 • ACR Convergence 2023
Distinct Cell-Bound Complement Activation Products Associate with Disease Activity and Immune Transcriptional Signatures in SLE
Gabriel Arguelles, Lynne Mitchell, Dennis Hourcade, John Atkinson, Elisha Roberson and Alfred Kim, Washington University School of Medicine, St. Louis, MO
Background/Purpose: Complement plays a central role in SLE, generating an array of bioactive soluble and cell-bound complement activation products (CB-CAPs) during disease activity. Data are…
Abstract Number: 2582 • ACR Convergence 2023
Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA
Hideto Takada¹, Kristen Demoruelle¹, Kevin Deane¹, Shohei Nakamura², Yasuhiro Katsumata³, Katsunori Ikari², Jane Buckner⁴, William H. Robinson⁵, Jennifer Seifert¹, Marie Feser¹, LauraKay Moss¹, Jill Norri⁶, Masayoshi Harigai³, Elena Hsieh¹, Michael Holer¹ and Yuko Okamoto², ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Stanford University, Palo Alto, CA, ⁶Colorado School of Public Health, Denver, CO

Background/Purpose: Production of ACPA following T and B cell interactions is a hallmark of ACPA+ RA. Recently identified peripheral helper T (Tph) cells have B…
Abstract Number: 0004 • ACR Convergence 2023
CD22 X CD79b Bispecific Ab Potently Inhibits B Cell Activation and Plasmablast Accumulation
Timothy Burwell¹, Jeffrey Hall¹, Suzanne Cole², Sarah Tursi¹, Isabelle Baribaud³, Kyle Bednar¹, Naresh Kumar¹, Julie Carman¹, Navin Rao² and Edith Janssen², ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cells contribute to the development and progression of autoimmune diseases through multiple mechanisms. Consequently, modulating B cell activation, B cell effector function, and…

« Previous Page
1
…
5
6
7
8
9
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].